Literature DB >> 7518659

Treatment of hyperthyroid disease.

I Klein1, D V Becker, G S Levey.   

Abstract

PURPOSE: To evaluate treatments for hyperthyroid disease. DATA SOURCES: Selected studies published during the last 20 years addressing the diagnosis, causes, and treatment of hyperthyroid disease. STUDY SELECTION: Studies were chosen based on their usefulness in addressing specific points in the treatment of hyperthyroid disease. DATA EXTRACTION: Various treatment principles extracted from the references form the basis for the conclusions and recommendations made here.
RESULTS: Hyperthyroid disease is a common endocrine disease. Although Graves disease is the most common cause of thyrotoxicosis, other primary and secondary causes exist. With classic signs and symptoms accompanied by confirmatory laboratory measures of thyroid hyperfunction, the diagnosis can be established firmly. Radioiodine is the preferred method to treat Graves disease; however, recent data concerning treatment with a combination of propylthiouracil and thyroxine require further evaluation to establish its efficacy. Radioiodine is also the preferred treatment for the other forms of hyperthyroid disease; however, patient-specific considerations in both may require patient-tailored therapies.
CONCLUSIONS: Hyperthyroid disease can be treated definitively for most patients. Palliative therapy with beta-adrenergic blockade is useful in some patients. Further studies are needed to determine whether more recently described treatments have improved efficacy and whether therapy directed specifically at the underlying immunologic cause of Graves disease can be used successfully.

Entities:  

Mesh:

Year:  1994        PMID: 7518659     DOI: 10.7326/0003-4819-121-4-199408150-00010

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  21 in total

Review 1.  Thyrotoxic atrial fibrillation.

Authors:  Malvinder S Parmar
Journal:  MedGenMed       Date:  2005-01-04

2.  The longer the antithyroid drug is used, the lower the relapse rate in Graves' disease: a retrospective multicenter cohort study in Korea.

Authors:  So Young Park; Bo Hyun Kim; Mijin Kim; A Ram Hong; Jun Park; Hyunju Park; Min Sun Choi; Tae Hyuk Kim; Sun Wook Kim; Ho-Cheol Kang; Jae Hoon Chung
Journal:  Endocrine       Date:  2021-04-15       Impact factor: 3.633

Review 3.  Propylthiouracil for alcoholic liver disease.

Authors:  Giuseppe Fede; Giacomo Germani; Christian Gluud; Kurinchi Selvan Gurusamy; Andrew K Burroughs
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

Review 4.  Thyroid hormone and heart failure.

Authors:  Ursula Maria Schmidt-Ott; Deborah Davis Ascheim
Journal:  Curr Heart Fail Rep       Date:  2006-09

5.  Oncology and nuclear medicine: a developing collaboration.

Authors:  G M Duchesne
Journal:  Eur J Nucl Med       Date:  1995-11

6.  Effects of oral propylthiouracil treatment on nitric oxide production in rat aorta.

Authors:  D J Grieve; S Fletcher; A A Pitsillides; K M Botham; J Elliott
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

7.  Total thyroidectomy for Graves' disease: compliance with American Thyroid Association guidelines may not always be necessary.

Authors:  Myrick C Shinall; James T Broome; Ratnam Nookala; Jennifer B Shinall; Colleen Kiernan; Lee Parks; Carmen C Solórzano
Journal:  Surgery       Date:  2013-09-26       Impact factor: 3.982

Review 8.  Adverse effects of thyroid hormone preparations and antithyroid drugs.

Authors:  L Bartalena; F Bogazzi; E Martino
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

Review 9.  Cardioselective beta-blockers for chronic obstructive pulmonary disease.

Authors:  S Salpeter; T Ormiston; E Salpeter
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

10.  Antithyroid Drug Treatment in Graves' Disease.

Authors:  Jae Hoon Chung
Journal:  Endocrinol Metab (Seoul)       Date:  2021-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.